Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Radiotherapy in Stage IV NSCLC
NCT03812549Phase 1Completed
- Sponsor
- Sichuan University
- Start
- Jan 2019
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Sichuan University. Primary endpoint: Number of Participants With Adverse Events and/or Dose Limiting Toxicities at 24 months. Started Jan 2019; status: completed.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03812549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812549.